Peregrine Pharmaceuticals reported $115.14M in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agenus AGEN:US $ 228.38M 19.32M
Amgen AMGN:US $ 5203M 1325M
AstraZeneca AZN:LN 395649.11M 43092.62M
Biocryst Pharmaceuticals BCRX:US $ 417.48M 21.98M
Bristol Myers Squibb BMY:US $ 10750M 1619M
Celldex Therapeutics CLDX:US $ 28.4M 3.11M
Chemocentryx CCXI:US $ 44.4M 3.82M
Eli Lilly And LLY:US $ 2622.9M 163.7M
GlaxoSmithKline GSK:LN 646500M 450200M
Immunogen IMGN:US $ 373.87M 63.79M
Intrexon XON:US $ 43.84M 3.52M
Karyopharm Therapeutics KPTI:US $ 82.25M 71.01M
Macrogenics MGNX:US $ 21.47M 25.86M
Mannkind MNKD:US $ 35.51M 31.74M
Minerva Neurosciences NERV:US $ 49.75M 5.19M
Newlink Genetics NLNK:US $ 79.51M 7.25M
Novartis NOVN:VX SF 3625M 10227M
Novavax NVAX:US $ 1375.59M 195.37M
Peregrine Pharmaceuticals PPHM:US $ 115.14M 11.03M
Repligen RGEN:US $ 596.51M 11.87M
Xencor XNCR:US $ 49.41M 28.86M